Cara Therapeutics - CARA Stock Forecast, Price & News

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics Price Performance

Shares of CARA Stock traded up $0.83 during trading on Friday, reaching $11.27. The company's stock had a trading volume of 644,466 shares, compared to its average volume of 442,395. The company has a market capitalization of $603.96 million, a price-to-earnings ratio of -6.33 and a beta of 1.02. The stock's 50-day moving average price is $8.99 and its 200 day moving average price is $10.24. Cara Therapeutics has a 1-year low of $7.40 and a 1-year high of $18.93.

Cara Therapeutics (NASDAQ:CARA - Get Rating) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04. The firm had revenue of $4.79 million during the quarter, compared to analysts' expectations of $15.82 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. On average, sell-side analysts anticipate that Cara Therapeutics will post -1.29 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Cara Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 13th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $26.80.

Insider Transactions at Cara Therapeutics

In related news, Director Jeffrey L. Ives sold 3,600 shares of the company's stock in a transaction on Friday, July 15th. The shares were sold at an average price of $9.05, for a total value of $32,580.00. Following the completion of the sale, the director now owns 15,476 shares in the company, valued at approximately $140,057.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 3.20% of the company's stock.